PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34482636-5	2022	Neratinib increased expression of Beclin1, ATG5, CD95, and FAS-L and decreased levels of multiple toxic BH3 domain proteins, MCL1, BCL-XL, FLIP-s, and ERBB1/2/4.	neratinib	0-9	autophagy related 5	Homo sapiens	43-47	
29163826-6	2017	Knock down of Beclin1 or ATG5 prevented HDAC inhibitors or neratinib from reducing ERBB1/3/4 and K-/N-RAS expression and reduced [neratinib + HDAC inhibitor] lethality.	neratinib	59-68	autophagy related 5	Homo sapiens	25-29	
29163826-6	2017	Knock down of Beclin1 or ATG5 prevented HDAC inhibitors or neratinib from reducing ERBB1/3/4 and K-/N-RAS expression and reduced [neratinib + HDAC inhibitor] lethality.	neratinib	130-139	autophagy related 5	Homo sapiens	25-29	
29219657-0	2018	The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.	neratinib	143-152	autophagy related 5	Homo sapiens	79-83	
29219657-4	2018	Knock down of Beclin1 or of ATG5 prevented neratinib and neratinib combined with sodium valproate / AR42 from reducing the expression of mutant N-RAS in established PDX and fresh PDX models of ovarian cancer and melanoma, respectively.	neratinib	43-52	autophagy related 5	Homo sapiens	28-32	
29219657-4	2018	Knock down of Beclin1 or of ATG5 prevented neratinib and neratinib combined with sodium valproate / AR42 from reducing the expression of mutant N-RAS in established PDX and fresh PDX models of ovarian cancer and melanoma, respectively.	neratinib	57-66	autophagy related 5	Homo sapiens	28-32